Meta AnalysisID 7306
吡喹酮与青蒿素类复方疗法治疗和控制人类血吸虫病的疗效和安全性：系统评价与Meta分析
CRD42023467293
What is the efficacy, safety and tolerability of combining Praziquantel and Artemisinin-based combination therapy in the treatment of human Schistosomiasis?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7306
- Evidence Id
- 15864
- Core Evidence Id
- 15864
- Source Meta Analysis Id
- 7294
- Herb2 Meta Analysis Id
- HBMA007294
- Crd Id
- CRD42023467293
- Title
- Efficacy and safety of Praziquantel and Artemisinin-based combination therapy for treatment and control of Human schistosomiasis: A systematic review and meta-analysis
- Review Question
- What is the efficacy, safety and tolerability of combining Praziquantel and Artemisinin-based combination therapy in the treatment of human Schistosomiasis?
- Study Type Included
- Randomized controlled trials and Non randomized Studies of Intervention of effects (NRSI)
- Condition Being Studied
- Praziquantel (PZQ) is recommended for the treatment and control of schistosomiasis. PZQ lacks activity against immature Schistosomes which mature after 8 weeks and became a source for continued transmission. There are reports of a reduction of PZQ efficacy, possibly due to the presence of PZQ resistance in juvenile Schistosome at the time of treatment. Artemisinin derivatives used as monotherapy have been reported to have high efficacy against juvenile worms apart from their antimalarial activity. Studies also have reported an improved cure rate when Praziquantel is combined with Artemisinin derivatives compared to using Praziquantel alone. However, there is raising concern on use of Artemisinin monotherapy combined with Praziquantel for schistosomiasis in Malaria endemic areas due to the risk of developing Artemisinin resistance to malaria parasites. Therefore, in Malaria –endemic areas, the use of Artemisinin-based combination therapy (ACT) with PZQ is the better option to delay risk of developing resistances to both Artemisinin and PZQ. Studies have reported the improved cure rate from the use of ACT combine with PZQ. However, we need to sum up and update the evidence on efficacy, safety and tolerability of ACT and PZQ combination therapy to guide clinical practice and policy for schistosomiasis treatment and control.
- Participant
- Children and adults with a confirmed infection by Kato-Katz thick smear for S. mansoni, S. japonicum, and by urine filtration technique for S. haematobium infection.
- Animal
- Human Disease Modelled
- Intervention
- Combination of Praziquantel with Artemisinin-based combination therapy (ACT)
- Comparator Control
- Praziquantel alone used as reference
- Main Outcome
- Primary outcome will be efficacy that will be assessed by two indicators; Parasitological cure rate defined as proportional of treated patients who were eggs positive at baseline and turned negative at three weeks post treatment and Egg reduction rate which will be measured by reduction in eggs/g of stool or eggs/10mls of urine at three weeks post-treatment . Measures of effect Comparison between the use of Praziquantel (monotherapy ) as gold standard for treatment of schistosomiasis and Praziquantel combined with ACT. The measure of effect for efficacy will be expressed in Relative Risk (RR) or Risk Difference (RD) between the intervention group and comparison group. We will present all measure of effects with a 95% Confidence interval
- Outcome Measure
- Additional Outcome
- Secondary outcomes is safety which will be assessed by looking at adverse events reported within four hours of drug intake. Measures of effect We will compare adverse events reported after four hours of drug intake between Praziquantel (monotherapy) and Praziquantel combined with ACT. The measure of effect for efficacy will be expressed in Relative Risk (RR) or Risk Difference (RD) between the intervention group and comparison group. We will summarize the continuous data using Mean and Standard Deviation (SD) and present all measure of effects with a 95% Confidence interval.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- MeSH headings have not been applied to this record
- Contact
- ADELINA PESHA [email protected]
- Organisational Affiliation
- KIBONG'OTO INFECTIOUS DISEASES HOSPITAL
- Funding Source
- NONE Grant number(s) State the funder, grant or award number and the date of award NONE
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Tanzania
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-10-16
- Registration Date
- 2023-10-27
- Anticipated Start Date
- 2023-10-15
- Anticipated Completion Date
- 2024-01-15
- Title Cn
- 吡喹酮与青蒿素类复方疗法治疗和控制人类血吸虫病的疗效和安全性：系统评价与Meta分析
- Title En
- Efficacy and safety of Praziquantel and Artemisinin-based combination therapy for treatment and control of Human schistosomiasis: A systematic review and meta-analysis
- Bilingual Status
- complete